Status:
COMPLETED
Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Multiple Myeloma
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
The primary purpose of this clinical study is to determine the recommended clinical doses of vorinostat (MK-0683) and bortezomib administered in combination to participants with relapsed and/or refrac...
Eligibility Criteria
Inclusion
- is ≥20 years of age.
- has an established diagnosis of MM based on the myeloma diagnostic criteria
- has received at least 1 but not more than 3 prior anti-myeloma regimens and has progressive disease after the most recent treatment regimen
- has adequate organ function
Exclusion
- has had a prior allogeneic bone marrow transplant or plans to undergo any type of bone marrow transplantation during the study
- has known hypersensitivity to any components of vorinostat or bortezomib
- has active hepatitis B or C, plasma cell leukemia, or is human immunodeficiency virus (HIV) positive
- has had prior treatment with vorinostat or histone deacetylase (HDAC) inhibitors
Key Trial Info
Start Date :
February 13 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 19 2012
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00858234
Start Date
February 13 2009
End Date
April 19 2012
Last Update
April 9 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.